REVIEW ARTICLE
Production and clinical development of nanoparticles for gene delivery
Jie Chen1, Zhaopei Guo1, Huayu Tian1 and Xuesi Chen1

Gene therapy is a promising strategy for specific treatment of numerous gene-associated human diseases by intentionally altering the gene expression in pathological cells. A successful clinical application of gene-based therapy depends on an efficient gene delivery system. Many efforts have been attempted to improve the safety and efficiency of gene-based therapies. Nanoparticles have been proved to be the most promising vehicles for clinical gene therapy due to their tunable size, shape, surface, and biological behaviors. In this review, the clinical development of nanoparticles for gene delivery will be particularly highlighted. Several promising candidates, which are closest to clinical applications, will be briefly reviewed. Then, the recent developments of nanoparticles for clinical gene therapy will be identified and summarized. Finally, the development of nanoparticles for clinical gene delivery in future will be prospected.

Molecular Therapy — Methods & Clinical Development (2016) 3, 16023; doi:10.1038/mtm.2016.23

INTRODUCTION
Gene therapy has drawn significant attention as a promising strategy for specific treatment of numerous gene-associated human diseases ranging from cancer, hemophilia, hypercholesterolemia, neurodegenerative diseases to autoimmune diseases.1–4 This strategy is to introduce genes into the target pathological tissues or cells by altering the expression of the endogenous genes to cure or prevent the progression of the related disease.1,4 Gene therapy has been widely studied in various areas, instead of conventional methods that usually fail to treat many diseases caused by genetic anomalies,7 and has become one of the most promising biomedical technologies for the clinical application.5,6 However, naked genetic molecules cannot be internalized efficiently by target cells because of their serum nuclease susceptibility, rapid renal clearance, phagocytic uptake, reduced uptake by target cells and toxic effect arose by immune response stimulation, which severely restricts their clinical application.8 With the developments of material sciences and the rapid progress of nanotechnology, nanosized materials for gene delivery have attracted worldwide attentions.11 Recently, some preliminary clinical trials of nanoparticles for gene delivery revealed promising effects.12,13 However, the development of safe, efficient, and controllable gene delivery nanoparticles for gene delivery is still now a bottleneck to successful clinical applications.14,15

Despite having been achieved some initiatory successes, the widespread clinical application of gene therapeutics for disease prevention and treatment meets many unavoidable challenges. The most important points are encapsulation efficiency, stability of nanoparticles, degradation in blood circulation, endocytosis by target cells, endosomal escape, delivery efficiency, and toxicity of pharmacology.16 To overcome these obstacles, many types of nanoparticles have been evaluated as gene carriers, which include lipid-based nanoparticles,17 polymer-based nanoparticles,18 and inorganic nanoparticles.19

In this review, we will particularly highlight the clinical development of nanoparticles for gene delivery rather than covering all the aspects of this field. Some promising candidates, which are closest to clinical applications in recent years, will be briefly reviewed. Then, the recent developments of nanoparticles for gene delivery will be identified and summarized in the clinical trials. Finally, the development of nanoparticles for clinical gene delivery in future will be prospected.

PRODUCTION OF NANOPARTICLES
With the great development of bioscience and nanotechnology, gene therapy shows an enormous potentiality in clinical application for many human serious incurable diseases.20 However, none of gene therapeutics based on nanoparticles has so far been approved by the US Food and Drug Administration (FDA). There are still several problems for the clinical application of nanoparticle-based gene therapy (Figure 1), including biodegradation and biocompatibility, aggregation in physiological fluids, nonspecific adsorption by undesired tissues, less efficient extravasation to reach target tissues, cellular internalization, and endosomal escape.12

Biodegradation is the primary factor for the clinical application of nanoparticle-based gene delivery.21 Poly(lactic-co-glycolic acid) has been an FDA-approved biodegradable polymer since 1969. In recent years, poly(lactic-co-glycolic acid) has been explored as a gene vector due to its stable and able to protect DNA from degradation during circulation in vivo.22,23 DNA/RNA can be encapsulated in poly(lactic-co-glycolic acid) nanoparticles by double-emulsion...
Nanoparticles for clinical gene delivery
Chen et al.

Effective cellular internalization of therapeutic genes is a critical process for the successful clinical application of nanoparticles for gene delivery. Although, several nanocarriers have been widely used to deliver therapeutic genes to the cells, it is still also urgent to improve the endocytosis of DNA/RNA to meet the ultimate goal of clinical application.\(^\text{35,56}\) Cell-penetrating peptides, with membrane translocation sequences or protein transduction domains, have been introduced on the surface of nanocarriers for gene therapy, which evokes quick cellular uptake of the gene delivery system via direct translocation in addition to the endocytic way.\(^\text{37,58}\) In addition, to increase the endosomal escape activity of nanoparticles, endosomolytic agents with the ability to destabilize the endosomal membrane have been introduced.\(^\text{19}\) In order to further optimize gene

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{schematization.png}
\caption{Schematization of nanoparticle-based gene therapy in vivo (Copyright 2014 Nature Publishing Group).}
\end{figure}
delivery, novel nanocarriers were developed by combining both endosomolytic agents and cell-penetrating peptides. Harashima and colleagues reported a stearylated derivative INF-modified R8-MEND dual functional gene delivery system and achieved detectable results both in vitro and in vivo.

In addition, the production of nanoparticles for clinical gene therapy should be designed according to the practical needs in clinic (Table 1). Firstly, the functions of nanocarriers should be tailored by the types and mechanisms of nucleic acid determinants, such as DNA, mRNA, siRNA, and miRNA. Secondly, the construction of

![Figure 2: The varieties of nanoparticles for the potential clinical gene therapy.](image)

| Functionalization       | Delivery systems                                      | Advantages                                      |
|-------------------------|------------------------------------------------------|-------------------------------------------------|
| PEGylation              | PEG-βCD; PEG-PEI                                     | Enhanced of stabilization; prevention of protein absorption; improved circulation time |
| Targeting               | RGD-HA-PEI-PBLG; R-PEG20C; transferrin-lipid         | Enhanced gene target efficacy in vivo, in vivo   |
| Stimulus response       | pH sensitive; light sensitive; redox sensitive        | Cross cell membrane; enhanced cellular uptake    |
| Cell penetrating        | p(DAH2-E/Alp)                                        | Cross cell membrane; improved endosomal escaping |
| Endosome escaping       | (Arg)7-FI-PNA                                         |                                                  |
| Nuclear localization    | PC/pDNA/NLS; VKRKKK-Rβ                                | Nuclear localization                            |

βCD, β-cyclodextrin; NLS, nuclear localization sequence; PC, β-cyclodextrin and polyethyleneimine; PEI, polyethyleneimine; R-PEG20C, cRGD-PEG-PAsp(DET)-cholesteryl.
the nanocarriers should also be changed by the variety of genetic diseases including cancers, optic atrophy, hypercholesterolemia, and dry eye, etc.\textsuperscript{13} Finally, plentiful of administration routes including local and systemic approaches also provide the opportunities and challenges to the application of nanoparticle-based gene therapy.\textsuperscript{64,65}

Clinical development of nanoparticles for gene delivery

Many clinical trials of gene therapy for preventing or treating genetic diseases are rapidly ongoing worldwide although none of the gene therapeutics based on nanoparticles have so far been approved by FDA.\textsuperscript{12}

Anderson \textit{et al.}\textsuperscript{66} conducted the first in-human clinical trial, which involved systemic administration of adenosine deaminase gene to a 4-year-old girl with severe combined immunodeficiency disease. An initial success of the trail was achieved, and then a research boom of gene therapy was set off worldwide. In 2000, Fischer and colleagues\textsuperscript{67} initiated a gene therapy trail for severe combined immunodeficiency-X1, an X-linked inherited disorder characterized by an early block in T and natural killer lymphocyte differentiation, based on the use of complementary DNA containing a retrovirus-derived vector and \textit{ex vivo} infection of CD34\textsuperscript{+} cells. After a 10-month follow-up period, T, B, and NK cell counts and function of the two patients were comparable to those of age-matched controls. However, the two youngest boys revealed the symptoms of leukemia 3-years after gene therapy, which was mainly due to the retrovirus vector integration in proximity to the proto-oncogene and triggered deregulated premalignant cell proliferation with unexpected frequency.\textsuperscript{68} Thus, the broad application of gene therapy was restricted severely by the safety concerns aroused by viral vectors.\textsuperscript{69}

Recently, nanoparticles are being investigated to utilize as gene delivery systems to overcome the delivery barriers due to their properties associated with safety, nonimmunogenicity,
Davis and colleagues reported the first nanoparticle-based gene delivery system named CALAA-01 in a phase-1 clinical trial against cancers. CALAA-01 consists of siRNA targeting the M2 subunit of ribonucleotide reductase (RRM2), cyclodextrin containing polymer, PEG steric stabilization agent, and transferrin targeting ligand for binding to transferrin receptors upregulated on cancer cells. The results showed that this “drug” could deliver siRNA to melanoma cells by systemic administration and demonstrated potent antiproliferative activity across multiple types of cancer cells.

Since then, many nanoparticle-based gene delivery systems have been developed for clinical trials. PEI has been carried out for local clinical gene therapy of various cancers. However, the substantial cytotoxicity severely hampered its further application and a range of modifications to PEI had been investigated. Polyethylene glycol-polyethyleneimine-cholesterol (PEG-PEI-cholesterol) was successfully developed as a gene delivery carrier for immunotherapy of epithelial ovarian by enhanced expression of cytokine interleukin-12. Lipid formation of nucleic acid shows the most clinical trials among nanoparticles for gene delivery. A phase-1 clinical trial for ALN-VSP, a lipid nanoparticle formulation encapsulating the siRNAs that can specifically target the mRNA of vascular endothelial growth factor (VEGF siRNAs), was initiated by Alnylam Pharmaceuticals and showed that systemically delivered lipid nanoparticles could induce the regression of liver metastases and improve the potentially sensitizing effect of chemotherapy. ALN-TTR02 was an intravenously delivered lipid-based siRNA formulation in patients with TTR amyloidosis. The safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of ALN-TTR02 were evaluated. The data showed that specific knockdown of up to 94% was achieved in serum TTR protein levels and the knockdown effect could sustain for 1 month. Furthermore, no infusion reactions were observed at the high dose of 0.3 mg/kg.

### Table 2 Nanoparticle-based gene therapy under clinical evaluation

| Delivery system | Product | Sponsor | Disease | Administration | Phase | Status | Gov identifier |
|-----------------|---------|---------|---------|----------------|-------|--------|----------------|
| PEI-based nanoparticles | BC-819/PEI | BioCancell | BC | Local | 2 | Active | NCT00595088 |
| | BC-819 | BioCancell | OC | IP | 1/2 | Completed | NCT00826150 |
| | DTA-H19 | BioCancell | PN | Local | 1/2 | Completed | NCT00711997 |
| | EGEN-001 | Gynecologic Oncology Group | Cancer | IP | 2 | Active | NCT01118052 |
| Lipid-based nanoparticles | TMK-080301 | National Cancer Institute | HM | IA | 1 | Completed | NCT01437007 |
| | TMK-080301 | Tekmira Pharmaceuticals Corporation | HC | IV | 1/2 | Recruiting | NCT02191878 |
| | TMK-080301 | Tekmira Pharmaceuticals Corporation | NET; ACC | IV | 1/2 | Completed | NCT01262235 |
| | Atu027 | Silence Therapeutics GmbH | ASC | IV | 1 | Completed | NCT00938574 |
| | ALN-TTR02 | Alnylam Pharmaceuticals | TTR-A | IV | 2 | Completed | NCT01617967 |
| | DOTAP-Chol-fus | MD Anderson Cancer Center | LC | IV | 1 | Completed | NCT0059605 |
| | DCR-MYC | Dicerna Pharmaceuticals | ST; MM; NHL | IV | 1 | Recruiting | NCT02110563 |
| | DCR-MYC | Dicerna Pharmaceuticals | HC | IV | 1/2 | Recruiting | NCT02314052 |
| | ND-L02-s0201 Injection | Nitto Denko Corporation | EHF | Local | 2 | Active | NCT01676259 |
| PLGA-based nanoparticles | siG12D LODER | Silenseed | PC | Local | 2 | Active | NCT01676259 |

### Table 3 Combination of gene therapy and chemotherapy under clinical evaluation

| Delivery system | Product | Sponsor | Disease | Administration | Phase | Status | Gov identifier |
|-----------------|---------|---------|---------|----------------|-------|--------|----------------|
| PEG-PEI-cholesterol | EGEN-001 + carboplatin + docetaxel | EGEN | ON | IP | 1 | Completed | NCT00473954 |
| PEG-PEI-cholesterol | EGEN-001 + PLD | Gynecologic Oncology Group | R/POEC; FTC; PPC | IP | 1 | Recruiting | NCT01489371 |
| PEG-PEI-cholesterol | GEN-1 + SNC | Celsion | EOC; FTC; PPC | IP | 1 | Recruiting | NCT02480374 |
| Lipid | SGT-53 + nab-paclitaxel/gemcitabine | SynerGene Therapeutics | MPC | IV | 2 | Recruiting | NCT02340117 |

ACC, adrenocortical carcinoma; ASC, advanced solid cancer; BC, bladder cancer; EHF, extensive hepatic fibrosis; HC, hepatocellular carcinoma; HM, hepatic metastases; IA, intra-arterial; LC, lung cancer; MM, multiple myeloma; NET, neuroendocrine tumors; NHL, non-Hodgkins lymphoma; OC, ovarian cancer; PC, pancreatic cancer; PEI, polyethyleneimine; PLGA, poly(lactic-co-glycolic acid); PN, pancreatic neoplasms; ST, solid tumors; TTR-A, transthyretin amyloidosis.
in the phase-2 study.\textsuperscript{74,75} Allovectin-7, which was consisted of DMRIE-DOPC and a plasmid DNA, had successfully passed phase-2 clinical trials, but failed to meet its endpoints in increasing percent DCR or overall survival in a phase-3 clinical trial for treatment of advanced metastatic melanoma and finally the development of this treatment had been abandoned.\textsuperscript{12,76} Nonetheless, various lipid-based formulations continued to be developed in clinic (Table 2).

Recently, great attentions have been paid to the clinical application of combination approaches of gene with drug, radiotherapy, photodynamic therapy, or immunotherapy.\textsuperscript{11,48} A phase-1 study of the safety and biological activity of intraperitoneal GEN-1 (IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer) administered in combination with standard neoadjuvant chemotherapy was carried out to diagnose with epithelial ovarian, fallopian tube, and primary peritoneal cancer (Table 3). A phase-2 study of the combination of intravenously administered SGT-53 (P53 gene therapy sponsored by SynerGene Therapeutics) and oral temozolomide was ongoing for the treatment of recurrent glioblastoma. SGT-53 nanodelivery system consisted of a cationic liposome, an antiferritin receptor single chain antibody fragment and the wtp53 plasmid DNA.\textsuperscript{48} This trial will evaluate the nanoparticle delivery to tumor site, the induction of apoptosis in the tumor, antitumor activity, and safety (Table 3).

Conclusion and outlook

In the past two decades, substantial nanoparticle-based gene therapies have been constructed in the treatment of various diseases due to the rapid development of nanotechnology and genomics.\textsuperscript{12} The clinical application of gene therapy is hindered by the challenges associated with its delivery system, including rapid degradation and clearance in circulation, insufficient half-life, nonspecific uptake, reduced uptake by target cells, inability to escape endosomes and toxic effect arose by immune response stimulation.\textsuperscript{12,27} Although several viral-based vectors have been used for clinical gene therapy due to their high transduction efficiency,\textsuperscript{78,79} they still face serious challenges, including adverse effects and high costs.\textsuperscript{80} Therefore, it is necessary to develop safe and effective nonviral gene delivery systems. Among them, nanoparticle-based delivery systems have shown their potential application in clinical gene therapy.\textsuperscript{13} Furthermore, many strategies have been introduced to improve the intelligences of nanoparticles for gene delivery systems, such as biodegraded, PEGylated, targeted, and modified with cell-penetrating peptides or endosomolytic agents.\textsuperscript{11,81,82}

Since the first cyclodextrin-based phase-1 clinical trial for gene therapy was achieved in 2010, a number of nanoparticle-based gene delivery systems have been developed for clinical trials.\textsuperscript{13} Most of them consisted of cationic polymer for binding nucleic acids, PEG steric stabilization agent, and targeting ligand for binding to the receptors on target cells. However, some of the clinical trials finally failed to meet their endpoints and none of gene therapeutics based on nanoparticles has so far been approved by FDA. To our knowledge, the primary obstacle comes from the complexity of the disease and the precise interpretation of its pathogenesis by molecular biological approach will be a prerequisite for effective clinical gene therapy. Moreover, successful clinical gene therapy is also seriously restricted by the safety and effectiveness of gene delivery systems. Despite these difficult conditions, gene therapy still owned its great potentiality for preventing or treating genetic diseases.

Further clinical progress of nanoparticle-based gene therapy will be facilitated by additional biological insights and nanotechnology into the key rate-determining steps that limit the effective therapy. Moreover, structure–function relationships, anatomical barriers, nucleic acids stability and availability, immunoreactivity, delivery routes are all major clinical challenges. It is expected that gene therapy based on local administrations can reach its goals and be approved by FDA more easily due to foreseeable features. Immunotherapy based on gene delivery will be a very promising approach for the treatment of genetically related diseases by subcutaneous injection. However, the systemic application of DNA/RNA will be seriously hindered by the complicated in vivo microenvironment. Particularly, it is impossible to completely avoid the possible cross-reactivity between nucleic acid drug and all body cells, which will bring about unexpected side effects by systemic therapies. Based on it, a secure targeted delivery strategy will be especially necessary. Finally, combination approaches of nanoparticle-based gene therapy with drug, radiotherapy, photodynamic therapy, immunotherapy or others will be the one of the most emphasis in future clinical studies.

CONFLICT OF INTEREST

The authors declare no conflict of interest.
19. Tian, H, Guo, Z, Chen, J, Lin, L, Xia, J, Dong, X et al. (2014). Gene therapy and DNA delivery systems. J Control Release 200: 97–105.
20. Ge, Z, Chen, Q, Osada, K, Liu, X, Tockary, TA, Uchida, S et al. (2014). Targeted gene delivery using polyplex mixtures with crowded PEG palisade and cRGD moiety for systemic treatment of pancreatic tumors. Biomaterials 35: 3416–3426.
21. Tian, H, Guo, Z, Lin, L, Jiao, Z, Chen, J, Gao, S et al. (2014). pH-responsive zwitterionic copolypeptides as charge conversional shielding system for gene carriers. J Control Release 174: 117–125.
22. Yuan, X, Naguib, S and Wu, Z (2011). Recent advances of siRNA delivery by nanoparticles. Adv Healthc Mater 1: 47–52.
23. Ikeda, Y and Nagasaki, Y (2014). Impacts of PEGylation on the gene and oligonucleotide gene delivery efficiencies of cationic helical polypeptides via balanced membrane penetration and endosomal escape. Biomaterials 35: 1302–1314.
24. Dong, X, Tian, H, Chen, L, Chen, J and Chen, X (2011). Biodegradable mPEG-b-P(MCC-g-PBLG) micellar nanoparticles of amphiphilic and cationic block copolymers for siRNA delivery. Biomaterials 32: 659–668.
25. Liu, S, Lee, J, Hwang, SR, Park, J, Jang, H, Huh, MS et al. (2014). TNF-α gene silencing using polymeric siRNA/thiolated glico chitosan nanoparticles for rheumatoid arthritis. Mol Ther 22: 397–408.
26. Kim, TI, Rothmund, T, Kissel, T and Kim, SW (2015). Bioreducible polymers with cell penetrating and endosome burning functionality for gene delivery systems. J Control Release 152: 110–119.
27. Ibraheem, D, Elaissari, A and Fessi, H (2014). Gene therapy and DNA delivery systems. Adv Healthc Mater 1: 337–357.
28. Sun, TM, Du, JZ, Yan, LF, Mao, HQ and Wang, J (2008). Self-assembled biodegradable polymeric nanoparticles as a new generation transfection delivery platform: a review. Eur J Pharm Biopharm 68: 427–443.
29. Ding, X, Zheng, N, Song, Z, Yin, L and Cheng, J (2014). Trigger-responsive, fast-degradable poly(β-amino ester) for enhanced DNA transfection and reduced toxicity. Biomaterials 35: 5006–5015.
30. Dong, X, Tian, H, Chen, L, Chen, J and Chen, X (2011). Biodegradable mPEG-b-P(ImCQ-p-OE) copolymers for efficient gene delivery. J Control Release 152: 135–142.
31. Xu, WF, Wang, YD, Li, SY, Ke, YZ, Yan, YC, Li, S et al. (2015). Efficient gene and siRNA delivery with a cationic poly polyglyceramide with amine moieties in the main chain. RSC Adv 5: 50425–50432.
32. Sun, TM, DU, JZ, Yan, LF, Mao, HQ and Wang, J (2008). High affinity gene delivery systems: potential, delivery challenges and strategies. Adv Drug Deliv Rev 61: 34–52.
33. Chitkara, D, Mittal, A and Mahato, RI (2015). miRNAs in pancreatic cancer: therapeutic potential, delivery challenges and strategies. Eur J Pharm Biopharm 91: 432–434.
34. Oupicky, D, Ogris, M, Howard, KA, Dash, PR, Ulbrich, K and Seymour, L (2002). Enhancement of gene delivery and biological tracking. Adv Peptide Sci 8: 523–536.
35. Kim, S, Webster, P and Davis, ME (2004). PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 83: 97–111.
36. Hongo, JW, Park, JH, Huh, KM, Chung, H, Kwon, IC and Jeong, SY (2004). PEGylated polyethyleneimine for in vivo local gene delivery based on lipiodolized emulsion system. J Control Release 99: 157–169.
37. Tian, H, Chen, J and Chen, X (2013). Nanoparticles for gene delivery. Small 9: 2034–2044.
38. Pack, DW, Hoffman, AS, Pun, S and Stayton, PS (2005). Design and development of polymers for gene delivery. Nat Rev Drug Discov 4: 581–593.
39. Ikeda, Y and Nagasaki, Y (2014). Impacts of PEGylation on the gene and oligonucleotide delivery system. J Appl Polym Sci 131: 40298.
40. Tian, H, Lin, L, Chen, J, Chen, X, Park, TG and Maruyama, A (2011). RGD targeting hyaluronic acid coating system for PEI-PBGL gene carriers. J Control Release 155: 47–53.
41. Ballarin-Gonzalez, B and Howard, KA (2012). Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions. Adv Drug Deliv Rev 64: 1717–1729.
42. Xu, SH, Kim, K, Choi, K, Kim, SH and Kwon, IC (2014). Targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy. Adv Healthc Mater 3: 1182–1193.
43. Tian, H, Guo, Z, Chen, J, Lin, L, Xia, J, Dong, X et al. (2012). PEI conjugated gold nanoparticles: efficient gene carriers with visible fluorescence. Adv Healthc Mater 1: 337–357.
44. Ikeda, Y and Nagasaki, Y (2014). Impacts of PEGylation on the gene and oligonucleotide gene delivery efficiencies of cationic helical polypeptides via balanced membrane penetration and endosomal escape. Biomaterials 35: 1302–1314.
45. Ikeda, Y and Nagasaki, Y (2014). Impacts of PEGylation on the gene and oligonucleotide gene delivery efficiencies of cationic helical polypeptides via balanced membrane penetration and endosomal escape. Biomaterials 35: 3443–3454.
74. Haussecker, D (2014). Current issues of RNAi therapeutics delivery and development. J Control Release 195: 49–54.
75. Wan, C, Allen, TM and Cullis, PR (2014). Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv Transl Res 4: 74–83.
76. Hersey, P and Gallagher, S (2014). Intralesional immunotherapy for melanoma. J Surg Oncol 109: 320–326.
77. Chen, Y, Gao, DY and Huang, L (2015). In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev 81: 128–141.
78. Kotterman, MA and Schaffer, DV (2014). Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet 15: 445–451.
79. Moreau, A, Vandamme, C, Segovia, M, Devaux, M, Guilbaud, M, Tilly, G et al. (2014). Generation and in vivo evaluation of IL10-treated dendritic cells in a nonhuman primate model of AAV-based gene transfer. Mol Ther Methods Clin Dev 1: 14028.
80. Iyer, AK, Duan, Z and Amiji, MM (2014). Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors. Mol Pharm 11: 2511–2526.
81. Yang, XC, Niu,YL, Zhao, NN, Mao, C and Xu, FJ (2014). A biodegradable pullulan-based vector via ATRP for liver cell-targeting gene delivery. Biomaterials 35: 3873–3884.
82. Yang, YY, Hu, H, Wang, X, Yang, F, Shen, H, Xu, FJ et al. (2015). Acid-labile poly(glycidyl methacrylate)-based star gene vectors. ACS Appl Mater Interfaces 7: 12238–12248.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/